
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Clene Inc. (CLNN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CLNN (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $27.83
1 Year Target Price $27.83
3 | Strong Buy |
3 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.5% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.34M USD | Price to earnings Ratio - | 1Y Target Price 27.83 |
Price to earnings Ratio - | 1Y Target Price 27.83 | ||
Volume (30-day avg) 6 | Beta 0.54 | 52 Weeks Range 2.28 - 6.90 | Updated Date 08/15/2025 |
52 Weeks Range 2.28 - 6.90 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5032.1% |
Management Effectiveness
Return on Assets (TTM) -49.62% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43446889 | Price to Sales(TTM) 92.39 |
Enterprise Value 43446889 | Price to Sales(TTM) 92.39 | ||
Enterprise Value to Revenue 124.13 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 8982750 | Shares Floating 6140786 |
Shares Outstanding 8982750 | Shares Floating 6140786 | ||
Percent Insiders 34.6 | Percent Institutions 17.85 |
Upturn AI SWOT
Clene Inc.

Company Overview
History and Background
Clene Inc., founded in 2012, focuses on developing bioenergetic nanocatalysis therapies for neurodegenerative diseases. It aims to improve neuronal survival and function through energy enhancement at the cellular level.
Core Business Areas
- Neurology: Develops therapies for neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Leadership and Structure
Rob Etherington serves as CEO. The company has a board of directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- CNM-Au8: An investigational gold nanocrystal suspension intended to enhance neuronal function. Currently undergoing clinical trials for multiple sclerosis, Parkinson's disease, and ALS. Its competitors are the other treatments for these diseases which include but are not limited to Biogen (BIIB), Teva Pharmaceuticals (TEVA), and Mitsubishi Tanabe Pharma (MTLFF).
Market Dynamics
Industry Overview
The neurodegenerative disease treatment market is large and growing due to an aging population. It is characterized by high unmet needs and significant R&D investment.
Positioning
Clene Inc. is a clinical-stage biotech company focused on a novel approach (nanocatalysis) within the neurodegenerative disease space. Its competitive advantage lies in its unique technology and potential for disease modification.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease treatments is estimated to be in the tens of billions of dollars annually. Clene is positioned to capture a share of this market if its therapies are approved.
Upturn SWOT Analysis
Strengths
- Novel nanocatalysis technology
- Potential for disease modification
- Experienced management team
- Focus on high unmet needs
Weaknesses
- Clinical stage company (high risk)
- Limited financial resources
- Dependence on clinical trial outcomes
- Potential for regulatory hurdles
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Advancements in nanotechnology
Threats
- Clinical trial failures
- Competition from existing therapies
- Regulatory setbacks
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- BIIB
- TEVA
- AMGN
Competitive Landscape
Clene Inc. faces competition from established pharmaceutical companies with approved therapies for neurodegenerative diseases. Its competitive advantage lies in its novel mechanism of action, but it faces the challenge of demonstrating clinical efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical development and securing funding.
Future Projections: Future growth is contingent on positive clinical trial outcomes and regulatory approvals for CNM-Au8. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and exploring partnerships with other companies.
Summary
Clene Inc. is a high-risk, high-reward clinical-stage company developing a novel therapeutic approach for neurodegenerative diseases. Its success hinges on positive clinical trial results and regulatory approvals. The company faces competition from established players and the inherent risks associated with drug development. Their unique technology could address a vast market need.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (Factset, etc.)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies involves significant risks, including the risk of losing your entire investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.